DELALUTIN Drug Patent Profile
✉ Email this page to a colleague
When do Delalutin patents expire, and when can generic versions of Delalutin launch?
Delalutin is a drug marketed by Bristol Myers Squibb and is included in two NDAs.
The generic ingredient in DELALUTIN is hydroxyprogesterone caproate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydroxyprogesterone caproate profile page.
Summary for DELALUTIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Patent Applications: | 5,401 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DELALUTIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for DELALUTIN
US Patents and Regulatory Information for DELALUTIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | DELALUTIN | hydroxyprogesterone caproate | SOLUTION;INTRAMUSCULAR | 010347-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bristol Myers Squibb | DELALUTIN | hydroxyprogesterone caproate | SOLUTION;INTRAMUSCULAR | 016911-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bristol Myers Squibb | DELALUTIN | hydroxyprogesterone caproate | SOLUTION;INTRAMUSCULAR | 016911-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |